Fig. 1 ZMAb improves survival of EBOV-challenged NHPs

Slides:

Advertisements

Similar presentations

Therapeutic Intervention of Ebola Virus Infection in Rhesus Macaques with the MB-003 Monoclonal Antibody Cocktail by James Pettitt, Larry Zeitlin, Do H.

Advertisements

Successful Treatment of Ebola Virus–Infected Cynomolgus Macaques with Monoclonal Antibodies by Xiangguo Qiu, Jonathan Audet, Gary Wong, Stephane Pillet,

Immune Parameters Correlate with Protection Against Ebola Virus Infection in Rodents and Nonhuman Primates by Gary Wong, Jason S. Richardson, Stéphane.

Competition binding assays.

In vivo prophylactic and therapeutic efficacy of C12G6 in mice

Fig. 2. Response to repeat dosing of chimpanzees with ARC-520.

Fig. 1 DMF promotes viral infection.

Fig. 7 Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors. Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors.

Fig. 6. Safety assessment in cynomolgus monkey.

CCR2+ monocytes are a relevant source of type I IFN in response to Af.

Fig. 4. Improved tumor response to docetaxel in TNBC and trastuzumab in HER2-amplified PDX models with the addition of S Improved tumor response.

Comparison of therapeutic efficacies of C12G6 and other bnAbs in mice

Survival and time to death of cynomolgus macaques following vaccination with AVA and subsequent lethal B. anthracis spore challenge (NHP preexposure prophylaxis.

Fig. 7. NAC in breast cancer patients promotes TMEM assembly and increased MENAINV expression. NAC in breast cancer patients promotes TMEM assembly and.

Fig. 5. Prophylactic and therapeutic efficacy of C12G6 in ferrets.

Fig. 7 Correlation of NHP and human ISGs.

Differentiation of AZD4785 from MAPK pathway inhibitors in vitro

Biocompatibility evaluation in vivo with a mouse subcutaneous implant

Fig. 3. The effect of VRC01 infusion on virus load in plasma and blood CD4 T cells during ART. The effect of VRC01 infusion on virus load in plasma and.

Fig. 1 ZIKV RNA in blood and tissues.

Consolidated Standards of Reporting Trials flow diagram of VRC trial

Fig. 1. Loss of circadian rhythms in iKO mice.

Fig. 2 AcPGP induces IL-8 and G-CSF release from human bronchial epithelial cells. AcPGP induces IL-8 and G-CSF release from human bronchial epithelial.

Fig. 2. Clinically actionable somatic genomic alterations in various tumor types. Clinically actionable somatic genomic alterations in various tumor types.

Fig. 5. Microarray analysis of tumors treated by dabrafenib, trametinib, or the combination of dabrafenib and trametinib with pmel-1 ACT or mock ACT. Microarray.

Fig. 1. Schematic showing the shedding of tumor DNA from head and neck cancers into the saliva or plasma. Schematic showing the shedding of tumor DNA from.

Fig. 3. Comparison of prediction performance.

Fig. 7 Bacterial dependency networks in IgA deficiency and HDs.

Fig. 6. TIV-09, but not MIV-09, induces an IFN signature in the blood of vaccinated individuals at day 1. TIV-09, but not MIV-09, induces an IFN signature.

Fig. 4. The effect of combined inhibition of BCL-2 and BCR-ABL on leukemia LT-HSC frequency. The effect of combined inhibition of BCL-2 and BCR-ABL on.

Immune response to vaccination with AVA in cynomolgus macaques (NHP preexposure prophylaxis study). Immune response to vaccination with AVA in cynomolgus.

In vivo release of doxycycline hyclate from the GRS in a swine model

Fig. 4 Deorphanization of quinine and mefloquine protein targets.

Fig. 2. Deficiency of neuronal HS leads to reduced neuroinflammation.

Fig. 3. Improved clinical responses to CD19 CAR-T cell immunotherapy after Cy/Flu lymphodepletion. Improved clinical responses to CD19 CAR-T cell immunotherapy.

Fig. 2. Bacterial/viral score in COCONUT-conormalized whole-blood validation data sets. Bacterial/viral score in COCONUT-conormalized whole-blood validation.

Fig. 5. Vitamin B12 supplementation in the host altered the transcriptome of P. acnes in the skin microbiota. Vitamin B12 supplementation in the host altered.

Fig. 1. Potent and selective down-regulation of KRAS mRNA and protein by AZD4785 in vitro and in vivo. Potent and selective down-regulation of KRAS mRNA.

HECTD2 knockdown ameliorates Pseudomonas-induced lung injury in vivo

Fig. 7 BMS reduces the elevated expression of type I IFN–regulated genes both ex vivo in blood from patients with lupus and in a phase 1 study of.

Fig. 1. Detection of circulating tumor DNA in CRPC patients.

The microchip-based drug delivery device and overview of study design

by Helen M. Lazear, Brian P. Daniels, Amelia K. Pinto, Albert C

Fig. 5. Octet BLI competition assay using D25 and motavizumab.

Fig. 2 PK dosing results. PK dosing results. (A) Plasma concentration of hPTH(1–34) versus time after release of 40-μg dose from implanted microchip device.

Fig. 3 Local Maraba treatment of TNBC tumors provides long-term systemic protection. Local Maraba treatment of TNBC tumors provides long-term systemic.

Representative CT and PET/CT images of three patients with NSCLCs

PD and efficacy of AZD4785 in KRAS mutant lung cancer xenograft models

Fig. 2 NDR2-deficient mice are more vulnerable to RNA viral infection.

Fig. 8. Purkinje cell quantification and hearing threshold in NPC cats administered IC HPβCD. Purkinje cell quantification and hearing threshold in NPC.

Fig. 3. Human liver tissue seed graft function.

Candesartan diminishes SynO-mediated morphofunctional responses in microglia. Candesartan diminishes SynO-mediated morphofunctional responses in microglia.

Fig. 1 Study design and antibody pharmacokinetics.

Delineating cancer evolution with single-cell sequencing

In vivo prophylactic and therapeutic efficacy of C12G6 in mice

Global effect of tree species diversity on forest productivity.

Two-mAb cocktail protects macaques against the Makona variant of Ebola virus by Xiangguo Qiu, Jonathan Audet, Ming Lv, Shihua He, Gary Wong, Haiyan Wei,

Exposure to SIV in utero results in reduced viral loads and altered responsiveness to postnatal challenge by Chris A. R. Baker, Louise Swainson, Din L.

Fig. 3. miR overexpression leads to increased cell proliferation as well as altered differentiation and metabolism in cardiomyocytes. miR

Fig. 5 Clustering of the distal gut microbiome, the C

Fig. 5 Topical vaginal application of DECON on alternate days is as effective as daily systemic ACV dosing. Topical vaginal application of DECON on alternate.

Fig. 5 LASV replication in cynomolgus monkeys.

Fig. 3. Association between peak CTL019 expansion and response.

Fig. 1. Schematic description of whole-exome or targeted next-generation sequencing analyses. Schematic description of whole-exome or targeted next-generation.

Fig. 8 Immune correlates of protection.

PD and efficacy of AZD4785 in a KRAS wild-type lung cancer PDX model

Fig. 3 Postnatal assembly of the humanized gut microbiota.

Fig. 4 Rotavirus induces the type I IFN pathway and release of ATP by tumor cells. Rotavirus induces the type I IFN pathway and release of ATP by tumor.

Fig. 6. Connectivity and mobility maps for Lesotho.

Fig. 1. Maps of Lesotho, a landlocked country within South Africa.

Presentation transcript:

Fig. 1 ZMAb improves survival of EBOV-challenged NHPs Fig. 1 ZMAb improves survival of EBOV-challenged NHPs. (A) Nine cynomolgus macaques were challenged with 1000 PFU of EBOV (red arrow). ZMAb improves survival of EBOV-challenged NHPs. (A) Nine cynomolgus macaques were challenged with 1000 PFU of EBOV (red arrow). Two groups (n = 4) were treated with ZMAb beginning either at 24 hours (days 1, 4, and 7; blue arrows) or at 48 hours (days 2, 5, and 8; pink arrows). A control animal (n = 1) received PBS (days 1, 4, and 7). The animals were sampled on treatment days plus days 14 and 21 (black arrows) and examined for (B) serum murine mAb levels by an Ebola virus–like particle (eVLP) ELISA, (C) survival, and (E) viremia measured by real-time RT-PCR (GEQ, genome equivalents) or (F) TCID50. Only PCR-positive samples were assayed for TCID50. (D) Historical cynomolgus macaque controls over the last 2 years, using the same challenge virus stock and dose, are presented with their time to death after challenge. All macaques have consistent symbols across panels. Xiangguo Qiu et al., Sci Transl Med 2012;4:138ra81 Copyright © 2012, American Association for the Advancement of Science